Savara Past Earnings Performance
Past criteria checks 0/6
Savara has been growing earnings at an average annual rate of 5.2%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 38.1% per year.
Key information
5.2%
Earnings growth rate
43.5%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -38.1% |
Return on equity | -74.0% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Savara: Today's Data 'Win' Rouses Market All Too Briefly
Jun 26Savara: The Binary Bet On Phase 3 Data
Jun 07Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?
Dec 14Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Feb 16Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Oct 12Savara's rare lung disorder drug gets promising innovative medicine status in UK
Aug 26Savara GAAP EPS of -$0.06 in-line
Aug 11Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?
Jan 24Is Savara (NASDAQ:SVRA) A Risky Investment?
Jul 05Savara: They Failed Once, But They Are Trying Again
Jun 07The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares
Mar 17Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares
Feb 26Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex
Nov 24Savara EPS misses by $0.01
Nov 05Revenue & Expenses Breakdown
How Savara makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -75 | 20 | 15 |
31 Mar 24 | 0 | -64 | 18 | 0 |
31 Dec 23 | 0 | -55 | 16 | 0 |
30 Sep 23 | 0 | -49 | 14 | 17 |
30 Jun 23 | 0 | -43 | 12 | 17 |
31 Mar 23 | 0 | -40 | 12 | 0 |
31 Dec 22 | 0 | -38 | 11 | 0 |
30 Sep 22 | 0 | -39 | 11 | 0 |
30 Jun 22 | 0 | -39 | 12 | 0 |
31 Mar 22 | 0 | -41 | 12 | 0 |
31 Dec 21 | 0 | -43 | 12 | 0 |
30 Sep 21 | 0 | -45 | 12 | 0 |
30 Jun 21 | 0 | -46 | 12 | 0 |
31 Mar 21 | 0 | -44 | 12 | 0 |
31 Dec 20 | 0 | -50 | 12 | 0 |
30 Sep 20 | 0 | -68 | 12 | -30 |
30 Jun 20 | 0 | -69 | 12 | -20 |
31 Mar 20 | 0 | -81 | 13 | -10 |
31 Dec 19 | 0 | -78 | 13 | 0 |
30 Sep 19 | 0 | -57 | 13 | 40 |
30 Jun 19 | 0 | -57 | 13 | 40 |
31 Mar 19 | 0 | -47 | 11 | 39 |
31 Dec 18 | 0 | -62 | 10 | 37 |
30 Sep 18 | 0 | -58 | 8 | 34 |
30 Jun 18 | 0 | -52 | 9 | 29 |
31 Mar 18 | 0 | -53 | 7 | 24 |
31 Dec 17 | 0 | -31 | 7 | 19 |
30 Sep 17 | 0 | -28 | 7 | 16 |
30 Jun 17 | 0 | -25 | 4 | 13 |
31 Mar 17 | 0 | -14 | 4 | 10 |
31 Dec 16 | 0 | -11 | 3 | 8 |
31 Dec 15 | 0 | -9 | 2 | 4 |
31 Dec 14 | 2 | -6 | 2 | 5 |
Quality Earnings: SVRA is currently unprofitable.
Growing Profit Margin: SVRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SVRA is unprofitable, but has reduced losses over the past 5 years at a rate of 5.2% per year.
Accelerating Growth: Unable to compare SVRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SVRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: SVRA has a negative Return on Equity (-74.01%), as it is currently unprofitable.